For the quarter ending 2025-09-30, MIST had $4,186K increase in cash & cash equivalents over the period. -$9,750K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -11,922 | -33,727 |
| Depreciation of property and equipment | 25 | 55 |
| Amortization of debt costs | 109 | 208 |
| Accretion of investment discount | 0 | -81 |
| Non-cash interest expense related to debt | 859 | 1,678 |
| Share-based compensation expense | 1,250 | 2,659 |
| Other receivables | -224 | -566 |
| Research and development tax credits receivable | -271 | 178 |
| Prepaid expenses | 1,829 | -1,092 |
| Operating lease assets and liabilities | -8 | -3 |
| Accounts payable and accrued liabilities | 1,273 | 1,213 |
| Net cash used in operating activities | -9,748 | -26,518 |
| Acquisition of property and equipment | 2 | 17 |
| Acquisition of short-term investments | 34,982 | 922 |
| Redemption of short-term investments | 0 | -44,466 |
| Net cash provided by (used in) investing activities | -34,984 | 43,527 |
| Proceeds from exercise of options | 122 | 36 |
| Proceeds from issuance of common shares, net of issuance costs | 23,143 | - |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | -2,573 | - |
| Proceeds from issuance of common stock warrants, net of issuance costs-Seriesa Common Warrants | 9,504 | - |
| Proceeds from issuance of common stock warrants, net of issuance costs-Seriesb Common Warrants | 13,416 | - |
| Proceeds from employee stock purchase plan | 160 | 140 |
| Cash provided by financing activities | 48,918 | 176 |
| Net increase (decrease) in cash and cash equivalents | 4,186 | 17,185 |
| Cash and cash equivalents at beginning of period | 25,314 | - |
| Cash and cash equivalents at end of period | 46,685 | - |
Milestone Pharmaceuticals Inc. (MIST)
Milestone Pharmaceuticals Inc. (MIST)